Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03134443
Other study ID # JXQF-XYP-1610
Secondary ID
Status Recruiting
Phase Phase 4
First received April 12, 2017
Last updated April 27, 2017
Start date December 1, 2016
Est. completion date June 1, 2018

Study information

Verified date April 2017
Source Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contact Lang Lv
Phone +86 010-84682600
Email bjlll@qfyy.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicenter, randomized, single-blind, placebo-controlled,phase 4 clinical trial to evaluate the efficacy and safety of andrographolide sulfonate in patients with acute tonsillitis


Description:

The patient after passing the screening, with the ratio of 1:1, were randomly assigned to experimental group and control group. Experimental group: On the basis of conventional therapy,combined with xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops. control group: Xiyanping injection simulation(0.9% normal saline) 10-20ml/d,the treatment method is the same as the experimental group. Treatment cycle: less than 7 days (the longest period of treatment is 7 days, if the clinical symptoms were relieved in the treatment, patients were stoped treatment).


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date June 1, 2018
Est. primary completion date December 31, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- 1.18-65 years, males or females;

- 2.patients met the acute tonsillitis diagnosis;

- 3.patients'all symptoms (including cough) appeared no longer than 72 h before inclusion to the trial

- 4.patients compliance is good, written informed consent was obtained from all participants before the study.

Exclusion Criteria:

- 1.Patients had a history of andrographolide sulfonate or andrographolide allergy.

- 2.Pregnancy, lactation, and absence of contraception in women of fertile age.

- 3.Judging by the researchers, Past or present illness of patients may affect to participate in the trial or affect the outcome of the study, including cardio-pulmonary diseases, malignant diseases, autoimmune diseases, hepatorenal disease, blood diseases, nervous system diseases, immune system diseases and endocrine diseases.

- 4.After checking, Patients with pulmonary tuberculosis, bronchial asthma, bronchial pneumonia, bronchiectasis, pneumoconiosis, silicosis, lung cancer, pulmonary infiltration or other allergic respiratory diseases and other chronic lung diseases

- 5.Patients using systemic steroids or other immunosuppressive therapy

- 6.Patients with severe cardiopulmonary dysfunction, abnormal liver and kidney function, blood system diseases.

- 7.Patients are alcohol (daily drink alcoholic wine is more than 40g) or drug abuse or drug addicts in the past year.

- 8.Patients were participated in any study of drug trials in the last 30 days.

- 9.According to the researchers' judgment, anyone who are not suitable for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Andrographolide sulfonate
Routine treatment for acute tonsillitis + Xiyanping injection
Andrographolide sulfonate simulation
Routine treatment for acute tonsillitis + Xiyanping injection simulation

Locations

Country Name City State
China The First Affiliated Hospital of Nanchang University Nanchang Jiangxi

Sponsors (1)

Lead Sponsor Collaborator
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary cured rate clinical symptoms and signs totally disappear, the period of lab tests return to normal is recorded less than 7 days
Secondary effective time window days range from treatment is received to the effectiveness is observed, and symptoms disappear less than 7 days
Secondary time from admission to recovery of sore throat the time of sore throat relief and purulent secretions complete disappearance of in the tonsils less than 7 days
Secondary time from admission to recovery of fever In the absence of other antipyretic drugs, the time from Xiyangping injection beganning to use to Axillary temperature below 37.5? , and last more than 24 hours without fever. less than 7 days
Secondary the incidence of complications Such as, the incidence of Acute otitis media, acute rhinitis, acute bronchitis, acute bronchitis,and so on. less than 7 days
Secondary bacterial eradication rate bacterial eradication rate=Sputum culture negative cases after treatment /sputum culture positive cases before treatment x 100% less than 7 days
Secondary days of antibiotic use oral anti infective Drugs use days and intravenous Anti infective Drugs use days are recorded less than 7 days
Secondary number of participants with treatment-related adverse events the total incidence of adverse events,the incidence of adverse events associated with Xiyanping injection, the incidence of patients with grade 3 through grade 4 adverse events that are related to study drug, graded according to NCI-CTC V4.0 .
Observe and record all adverse events and serious adverse events, including physical examination, vital signs, laboratory tests (Hematology, blood biochemistry, urine routine, stool routine), ECG changes and so on.
less than 7 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03704506 - Registration of the Study of Reyanning Mixture Phase 4
Active, not recruiting NCT04682964 - Bacteriophage Therapy in Tonsillitis Phase 3
Completed NCT04537819 - Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute Tonsillitis N/A
Not yet recruiting NCT02715037 - Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis N/A
Completed NCT01363531 - Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies Phase 4